• Human LILRA3/CD85e protein (Recombinant) (C-His) (STJP001323)

Human LILRA3/CD85e protein (Recombinant) (C-His) (STJP001323)

SKU:
STJP001323

Current Stock:
Host: HEK293 cells
Reactivity: Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Recombinant-Human LILRA3/CD85e-C-His protein was developed from hek293 cells and has a target region of C-His. For use in research applications.
Formulation: Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4.
Gene Symbol: LILRA3
Gene ID: 11026
Uniprot ID: LIRA3_HUMAN
Immunogen: Recombinant Human LILRA3/CD85e Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Gly24-Glu439) of Human LILRA3 (Accession #NP_006856.3) fused with a 6×His tag at the C-terminus.
Post Translational Modifications N-glycosylation is required for ligand binding.
Function Acts as soluble receptor for class I MHC antigens. Binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1 or LILRB2. Binds with high affinity to the surface of monocytes, leading to abolish LPS-induced TNF-alpha production by monocytes.
Protein Name Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 3
Cd85 Antigen-Like Family Member E
Immunoglobulin-Like Transcript 6
Ilt-6
Leukocyte Immunoglobulin-Like Receptor 4
Lir-4
Monocyte Inhibitory Receptor Hm43/Hm31
Cd Antigen Cd85e
Database Links Reactome: R-HSA-198933
Reactome: R-HSA-6798695
Cellular Localisation Secreted
Alternative Protein Names Leukocyte Immunoglobulin-Like Receptor Subfamily A Member 3 protein
Cd85 Antigen-Like Family Member E protein
Immunoglobulin-Like Transcript 6 protein
Ilt-6 protein
Leukocyte Immunoglobulin-Like Receptor 4 protein
Lir-4 protein
Monocyte Inhibitory Receptor Hm43/Hm31 protein
Cd Antigen Cd85e protein
LILRA3 protein
ILT6 protein
LIR4 protein

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance